By Aveluro Research Team · Editorial policy
DBD (DBD) is a company in Vietnam's Health Care sector, listed on HOSE. The stock last traded at 49,000 VND, little changed on the session, giving a market capitalization of 4.8 trillion VND.
On valuation, DBD trades at a price-to-earnings ratio of 16.6 and a price-to-book of 2.7. That is a discount to the Health Care sector average P/E of 22.2. Return on equity of 16.0% points to solid profitability relative to the company's equity base, above the sector average of 10.4%. Trailing earnings per share stand at 3,082 VND.
Aveluro tracks 3 news items mentioning DBD, where recent coverage skews positive (67% of articles). The most recent catalyst was a strategic partnership event — "Bidiphar (DBD) Launches Large-Scale Digital Transformation with SAP S/4HANA". Aveluro's composite model rates DBD 6.7/10 (Buy), blending news sentiment, price momentum, and fundamentals.
Comparable names in the Health Care sector include AGP, AMV and APC.
What matters now
Bidiphar (DBD) Launches Large-Scale Digital Transformation with SAP S/4HANA
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.